Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 25, 2014 Phillip Broadwith	Generics triumph in anti-inflammatory patent battle Pfizer has settled a long-running patent dispute with generics heavyweights Teva and Actavis, which will allow them to produce generic versions of Pfizers non-steroidal anti-inflammatory drug Celebrex (celecoxib) in the US.
The Motley Fool August 13, 2007 Rich Duprey	U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept.
The Motley Fool March 13, 2008 Stephen Albainy-Jenei	Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex.
The Motley Fool March 29, 2011 Brian Orelli	Much More Than a Generic Lawsuit The Supreme Court will decide generic-drug makers fate.
The Motley Fool June 29, 2007 Rich Duprey	No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
InternetNews December 14, 2004 Roy Mark	Court Rules RIM Infringed A federal appeals court ruled today that a district court properly determined that Research in Motion infringed on the patents on NTP, but still sent the case back to the district court for further review of damages.
Chemistry World June 4, 2014 Phillip Broadwith	Generics giants jostle over pain drug The US Food and Drug Administration has approved the first batch of generic competitors to Pfizer's non-steroidal anti-inflammatory Celebrex (celecoxib).
InternetNews March 13, 2006 Roy Mark	Feds Side Against eBay in Patent Case The United States government is siding with a Virginia patent holder that eBay willfully infringed on its patents and should be barred from using its popular "Buy It Now" feature, which allows a buyer to purchase an item at a set price.
InternetNews August 28, 2009	Dell, HP Side With Microsoft on Word Appeal Microsoft gained some help this week from its two largest PC partners who asked the court to let them join in the company's Word lawsuit as so-called "friends of the court."
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
InternetNews May 15, 2006 Roy Mark	Supreme Court Sides With eBay The U.S. Supreme Court ruled today that both a district and a federal appeals court erred in determining whether a permanent injunction is due to MercExchange in its patent-infringement battle with online auction giant eBay.
InternetNews May 15, 2006 Roy Mark	High Court Bounces Buy It Now Injunction Justices rule eBay may continue to offer service and orders a new review of permanent injunction sought by MercExchange.
Chemistry World August 24, 2009 Sarah Houlton	Indian court dismisses Bayer's patent law case Bayer has failed in its attempt to stop Indian regulators giving marketing authorization to a generic version of its kidney cancer drug Nexavar (sorafenib), despite its 20 year patent having only been granted last year.
Managed Care September 2007 Martin Sipkoff	Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.
The Motley Fool September 7, 2007 Brian Orelli	Fighting the Generics Next Door Pfizer tries to stop patients from switching from it's patented Lipitor to generic Zocor by doing an observational study of patients on both medications.
InternetNews February 26, 2008	Court Rules on Microsoft Office Patent Case Microsoft will owe a Guatemalan inventor somewhere between 4 cents and $2 per copy of Office sold.
The Motley Fool July 30, 2007 Brian Orelli	Is Par Pharmaceutical Settling for Less? The generic drugmaker avoids going to court in some recent cases. Patent lawyers are the lifeblood of a generic drugmaker, and investors should want them to act as aggressively as possible so that Par can expand its product line.
The Motley Fool March 30, 2009 Brian Orelli	Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore.
InternetNews June 25, 2007 Roy Mark	Court Raises Possible Vonage Injunction Relief Vonage tells appeals court that an injunction isn't necessary even if court upholds the VoIP provider infringed on Verizon patents.
InternetNews September 4, 2009	Microsoft Gets OK to Keep Selling Word Now that the injunction is on hold, the company's next focus is on its appeal.
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.
Managed Care September 2007	Income Said To Influence Use of Generics An observational analysis of pharmacy claims collected from 2001 to 2003 finds that where a person lives and the socioeconomic implications of that location have a lot do with his use of generic drugs.
InternetNews January 8, 2010	Microsoft Again Appeals i4i Patent Judgment Microsoft seeks rehearing by both the original appeals court panel as well as by all of the judges sitting together.
Managed Care November 2005	Recently Introduced Generics Helped Pbm Control Its Costs The top five generic drugs released over the past three years reduced pharmacy spending by 4.8 percent largely due to the timing of the release of generic products to the market.
American Family Physician March 15, 2004	STEPS Memantine (namenda) for moderate to severe alzheimer's disease
The Motley Fool January 21, 2004 Alyce Lomax	Forest Labs' High Hopes Alzheimer's treatment drug Namenda seems to be Forest's strong suit.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
Pharmaceutical Executive October 1, 2011	30 Years of Pharma: Perspective in Numbers, Part 3 Top 10 generics companies.
InternetNews March 12, 2010	Microsoft Loses Another Round in i4i Case In latest setback in patent case, appeals court reiterates that Microsoft's infringement was "willful," while both sides wait to see if the court will agree to hear Microsoft's en banc appeal.
The Motley Fool January 26, 2011 Brian Orelli	Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool September 19, 2006 Brian Lawler	Barr's Winning Bid The pharmaceutical wins its tug-of-war for generic drug firm Pliva. Investors would be smart to watch for any potential teething problems from the much larger and busier Barr.
Entrepreneur September 2006 Jane Easter Bahls	Toppling Trolls Patent trolls take a hit in a Supreme Court ruling.
InternetNews September 26, 2007 Caron Carlson	Vonage Dealt Sprint Nextel, Verizon Patent Blows VoIP provider Vonage, in the midst of Verizon appeals, takes a Sprint Nextel patent blow.
InternetNews April 2, 2010	Microsoft Loses Bid for Appeal in i4i Patent Case Court denies Microsoft's long-shot request for a full "en banc" hearing to appeal its patent-infringement loss against the small Toronto firm i4i.
Pharmaceutical Executive October 1, 2005 Glass & Worrell	Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
Chemistry World July 10, 2009 Sarah Houlton	Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.
Knowledge@Wharton	Drug Companies and the Patent Game: Fair Play or Foul? Is legal maneuvering a legitimate attempt by the big pharmaceutical companies to recover the huge costs of developing new drugs? Or are the brand-name firms inappropriately gaming the system for their own benefit, to the detriment of consumers and insurance companies?
The Motley Fool October 18, 2006 Rich Duprey	FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool August 1, 2008 Brian Orelli	Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line.
Chemistry World January 28, 2014 Phillip Broadwith	Actavis sells off Chinese subsidiary Generic drugs heavyweight Actavis is selling off a subsidiary based in Foshan, China. The business is being bought by Zhejiang Chiral Medicine Chemicals for an undisclosed sum.
Managed Care December 2005 David S. Geldmacher	The Cost Benefit to Health Plans of Pharmacotherapy for Alzheimer's Disease As with other chronic diseases of aging, early diagnosis and pharmacologic therapy may reduce the costs for enrollees with Alzheimer's disease. This article reviews patient and caregiver outcomes associated with reduced health care costs and their implications for Managed Care Organizations.
The Motley Fool December 30, 2011 Brian Orelli	A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.